Rasagiline (Azila) standard usage and dosage and recommended medication regimen

Rasagiline (Rasagiline) is a selective, irreversible monoamine oxidase B (MAO-B) inhibitor, mainly used to treat Parkinson's disease. By inhibiting the breakdown of dopamine, rasagiline can increase dopamine concentrations in the brain, thereby improving motor symptoms in patients with Parkinson's disease. The drug can be used alone in early-stage Parkinson's disease or in combination with levodopa in patients with mid-to-late stage disease to delay the progression of symptoms and reduce the "on-off" phenomenon.

The usual recommended dose for adults is Daily oral administration 1 mg, administered once, without the need to adjust the dose according to meals. The drug can be taken with water or food for stable absorption. In adults with normal renal or hepatic function, no dosage adjustment is necessary. If the patient is complicated by severe liver damage, he or she should use it with caution or adjust the dosage under the guidance of a doctor to avoid drug accumulation leading to adverse reactions.

Rasagiline can be used as a single agent to treat patients with early-stage Parkinson's disease, or in combination with levodopa for patients whose symptoms are not fully controlled. In the combination treatment regimen, rasagiline is mainly used to prolong the efficacy of levodopa and reduce the occurrence of the OFF period. It is generally recommended that the medication time be fixed at the same time every day to maintain stable blood concentration and improve efficacy and medication compliance.

During the use of rasagiline, patients should be careful to avoid concurrent use with other MAO inhibitors, high-tyramine-containing foods or drugs (such as certain antidepressants) to prevent hypertensive crisis or drug interactions. Regularly follow up with your doctor to evaluate symptom improvement, motor function and adverse reactions, and decide whether to continue or adjust the medication regimen based on efficacy and tolerability. For elderly patients or those with multiple underlying diseases, medication monitoring should be strengthened.

Reference link:https://www.drugs.com